<DOC>
	<DOCNO>NCT01240928</DOCNO>
	<brief_summary>This phase Ib trial evaluate safety tolerability MK-2206 give combination exemestane +/- goserelin pre- post-menopausal patient hormone receptor-positive metastatic breast cancer .</brief_summary>
	<brief_title>MK-2206+Endocrine Therapy Patients With Hormone Receptor-Positive Breast Cancer</brief_title>
	<detailed_description>The phase II portion trial list separate NCT number .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Goserelin</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<criteria>1 . Clinical stage IV invasive mammary carcinoma , document histological analysis , ERpositive and/or PRpositive immunohistochemistry ( IHC ) , previous endocrine therapy metastatic setting metastatic recurrence within 6 month adjuvant endocrine therapy . May measurable nonmeasurable disease , allow . Any number prior hormone chemotherapy agent acceptable 2 . Female ≥ 18 year age day sign informed consent 3 . Performance status 0 1 ECOG Performance Scale 4 . Adequate organ function indicate follow laboratory value : Hematological : Absolute neutrophil count ( ANC ) ≥ 1,500 /μL Platelets ≥ 100,000 /μL Hemoglobin ≥ 9 g/dL Renal : Serum creatinine calculate creatinine clearance† ≤ 1.5 x upper limit normal ( ULN ) OR ≥60 mL/min patient creatinine level &gt; 1.5 x institutional ULN Hepatic : Serum total bilirubin ≤ 1.5 x ULN OR direct bilirubin ≤ ULN patient total bilirubin level &gt; 1.5 x ULN AST ( SGOT ) ALT ( SGPT ) ≤ 2.5 x ULN ≤5 x ULN patient know liver metastasis Coagulation : Prothrombin time ( PT ) /INR ≤ 1.2 x ULN Partial thromboplastin time ( PTT ) ≤ 1.2 x ULN Metabolic : HBA1C ≤ 8 % † Creatinine clearance calculate per institutional standard ‡ Fasting define least 8 hour without oral intake 5 . Female patient childbearing potential must negative serum urine pregnancy test βhCG within 72 hour prior receive first dose study medication 6 . Postmenopausal female subject define prior protocol enrollment following : At least 55 year age Under 55 year age amenorrheic least 12 month folliclestimulating hormone ( FSH ) value ≥ 40 IU/L estradiol level &lt; equal 20IU/L Prior bilateral oophorectomy prior radiation castration amenorrhea least 6 month 7 . Patient , patient 's legal representative , voluntarily agree participate give write informed consent 8 . Able swallow capsule surgical anatomical condition preclude swallow absorb oral medication ongoing basis 9 . May receive concurrent radiation therapy painful bone metastasis area impend bone fracture long radiation therapy initiate prior study entry . Those received prior radiotherapy must recover toxicity induce treatment ( toxicity grade ≤ 1 ) 1 . Chemotherapy , radiotherapy , biological therapy within 3 week ( 6 week nitrosoureas , mitomycin C bevacizumab ) , recover adverse event due previous agent administer 4 week prior Study Day 1 . If residual toxicity prior treatment , toxicity must ≤ Grade 1 2 . Must least 4 week postmajor surgical procedure , surgical wound must fully heal 3 . Currently participate participate study investigational compound device within 30 day Study Day 1 4 . Known active CNS metastasis and/or carcinomatous meningitis . However , patient CNS metastasis complete course therapy would eligible study provide clinically stable least 1 month prior entry define : ( 1 ) evidence new enlarge CNS metastasis ( 2 ) steroid use minimize surround brain edema 5 . Primary central nervous system tumor 6 . Known hypersensitivity component study drug analog 7 . History current evidence clinically significant heart disease include : congestive heart failure , unstable angina pectoris , cardiac arrhythmia , history current evidence myocardial infarction last 6 month , and/or current ECG trace abnormal opinion treat Investigator , baseline QTc prolongation &gt; 450 msec ( Bazett 's Formula ) . Medications include Arizona CERT Lists 1 2 ( Appendix D ) must exclude . The concomitant use drug associate increase risk QT prolongation avoid patient congenital long QT syndrome ( Appendix D , Arizona CERT List 3 ) . Similarly , concomitant use drug weakly associate QT prolongation generally avoid ( Appendix D , Arizona CERT List 4 ) . Arizona CERT List 3 4 drug use discretion Investigator restrict applicable . Any therapy give drug use caution , patient receive medication carefully monitor . 8 . Evidence clinically significant bradycardia ( HR &lt; 50 ) , history clinically significant bradyarrhythmias sick sinus syndrome , 2nd degree AV block ( Mobitz Type 2 ) , patient take beta blocker , nondihydropyridine calcium channel blocker , digoxin 9 . Uncontrolled hypertension ( i.e. , 160/90 mHg SiBP ) . Patients control antihypertensive medication allow enter study 10 . At significant risk hypokalemia ( e.g. , patient high dose diuretic , recurrent diarrhea ) 11 . Poorly control diabetes define HbA1C &gt; 8 % 12 . History current evidence condition , therapy , lab abnormality might confound study result , interfere patient 's participation full study duration , best interest patient participate , opinion treat Investigator 13 . Known psychiatric substance abuse disorder would interfere cooperation trial requirement 14 . Patient , time signing informed consent , regular user ( include `` recreational use '' ) illicit drug recent history ( within last year ) drug alcohol abuse 15 . Pregnant breastfeeding , expect conceive father child within project duration study 16 . Human Immunodeficiency Virus ( HIV ) positive 17 . Known history Hepatitis B C active Hepatitis A 18 . Symptomatic ascites pleural effusion . Patient clinically stable follow treatment condition eligible 19 . Receiving treatment oral corticosteroid ( note : inhaled corticosteroid permit )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
</DOC>